About ImQuest

ImQuest Life Sciences will become a leader in the
development of exciting new drugs for unmet medical
needs throughout the world.

About ImQuest Life Sciences

ImQuest Life Sciences has broad-based interest in infectious disease and the development of drugs which inhibit these organisms through novel targets and means of intervention. Although vaccine development has been successful in many areas of infectious disease, significant unmet medical needs still remain with organisms such as HIV and hepatitis C virus. In many cases, despite the presence of effective vaccines, great numbers of people remain chronically infected with organisms that will cause significant long term health problems, such as with hepatitis. ImQuest Life Sciences is working with our partners to develop new therapies for infectious disease caused by viral, bacterial and fungal pathogens, especially in the areas of HIV, hepatitis B and C virus, influenza and other respiratory pathogens, herpes viruses and other emerging or re-emerging viral, bacterial and fungal infections.

Our Mission

ImQuest Life Sciences will develop new, novel, first in class drugs for the treatment of infectious disease, cancer and inflammation. We will fulfill this mission by developing key strategic alliances and partnerships with individuals, academic institutions, biotechnology and pharmaceutical companies which possess key technology requiring the resources of ImQuest Life Sciences to achieve drug development success. ImQuest Life Sciences will become a leader in the development of exciting new drugs for unmet medical needs throughout the world, providing new therapeutic resources for the effective treatment and prevention of human disease.

Our Strategy

ImQuest Life Sciences will form strategic drug development alliances with individuals, academic institutions, biotechnology companies and pharmaceutical companies which possess novel drug development strategies and technology that will facilitate the development of new drugs for the treatment of infectious disease, cancer and inflammation. Our portfolio development strategy has been facilitated by our alliance with ImQuest BioSciences, an independent provider of critical drug development and consultative services to the pharmaceutical industry, in light of their deep and broad experience with the development of therapeutic agents for human disease. In addition to developing our own proprietary technologies, ImQuest Life Sciences will provide a much needed vehicle for the clients of ImQuest BioSciences to add significant value to their portfolio through the performance of ImQuest-sponsored advanced preclinical pharmacology and toxicology and Phase 1 and 2 human clinical trials. In this way, ImQuest Life Sciences will assist in the provision of the all-important proof of concept studies for novel first in class agents and these studies will be performed by an experienced team of investigators.

Other Links

Meet the Management

Directors and Advisors

Our Focus

ImQuest Life Sciences is currently focusing on the following drug development programs, through the formation of alliances and partnerships as well as through exclusive world wide licensing:

Therapies for the treatment of HIV

Topical microbicides for the prevention of transmission of HIV and other sexually transmitted infections

Therapies for the treatment of HBV and HCV

Therapies for the treatment of cancer